Sex Differences Regarding the Effect of Dietary Vitamin E on the Liver and Metabolic Profile.

Background and Aims Non-alcoholic fatty liver disease (NAFLD) is characterised by lipid droplet accumulation in the hepatocytes and affects approximately 20-30% of the general population. Currently, there are no approved pharmacological agents available to treat NAFLD. There is growing evidence supporting the potential benefits of Vitamin E in reducing steatosis and lobular inflammation in non-diabetic patients with NAFLD. Despite numerous trials conducted to assess the efficacy of vitamin E supplementation in patients with NAFLD, there is a lack of understanding of its preventative effects.